Table S1. Overview of previous studies in ALL on associations between SNPs and MTX levels, MTX-related toxicity

	High MTX levels/ Poor clearance		Hematotoxicity		Hepatotoxicity/ Nephrotoxicity		Mucositis		Other Toxicity	
SNPs	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
SLCO1B1 rs4149056	(+)[1] (-)*	[2-5]	(+)[1] (-)*	[2, 3]	(+)[1]	[5]	(+)[1]	[4, 6]		
SLCO1B1 rs11045879	(+)[7-9]	[4, 5, 10]				[5]	(-)[8]	[4]		
SLCO1B1 rs2306283	(+)[11]	[4]	(+)[11]		(+)[11]		(+)[11]	[4]		
SLCO1B1 rs4149081	(+)[7-9] (-)[6]						(-)[8]			
SLC19A1 rs2838958	(+)*	[4]		[12]				[4, 12]		[12]
SLC19A1 rs3788200	(+)*	[4, 10]						[4]		
ABCC2 rs3740065	(+)[10]	[13]								
ABCC2 rs717620	(+)[2, 13]	[3, 10, 14, 15]	(+)[2, 13]	[3, 14]		[13, 15]	(+)[13]			[13]
ABCC2 rs2273697		[14]		[14]	(+)*					
ABCC4 rs9302061		[10]								
ABCC4 rs7317112	(-)[6]	[10]					(-)[6]			
MTRR rs1801394	(+)* (-)[6]	[16, 17]		[16, 17]	(-)*	[16]		[6, 17]		[16]
MTHFR rs1801131	(+)[18]	[3, 5, 7, 15-17, 19-23]	(+)[18, 22, 24-26] (-)[17, 27-29]	[3, 16, 19-21, 23, 30-32]	(+)[18, 26] (-)[5, 27, 28]	[15, 16, 19-21, 23, 30, 31, 33]	(+)[24]	[16, 17, 20, 21, 23, 30-33]	(-)[31]	[16, 20, 23, 24, 32-34]
MTHFR rs1801133	(+)[5, 15, 17-19, 21, 35, 36] (-)[22]	[2, 3, 7, 16, 20, 23, 37]	(+)[3, 19, 21, 27, 29, 31, 36, 38] (-)[18, 22, 25, 39]	[2, 16, 17, 20, 23, 24, 28, 30, 32]	(+)[5, 21, 26, 27, 36] (-)[18, 39]	[15-17, 19, 20, 23, 28, 30, 31, 33]	(+)[17, 20, 24, 40] (-)[37]	[16, 21, 23, 30-33]	(+)[24, 26, 27, 34, 35]	[16, 20, 23, 31-33]

The numbers refer to the references. Other toxicity: toxicity score, nausea, vomiting, diarrhea, skin, and neurological toxicity; **(+)**: Mutant-type is associated with high MTX plasma levels/ poor clearance/ toxicity; **(-)**: Wild-type is associated with less toxicity; No: no association of SNPs with high MTX plasma levels/ poor clearance/ toxicity; *: association that was found in the current study.

References

1. H. N. Zhang, X. L. He, C. Wang *et al*: Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate. *Pediatr Blood Cancer* 2014, 61(12):2203-2207.
2. R. H. Razali, M. N. F. Noorizhab, H. Jamari *et al*: Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL).

Pediatr Hematol Oncol 2020, 37(3):185-197.

3. N. K. Zgheib, M. Akra-Ismail, C. Aridi *et al*: Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. *Pharmacogenet Genomics* 2014, 24(8):387-396.
4. S. Liu, L. Wang, Ch. Gao *et al*: Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. *Oncotarget* 2017.
5. H. Fukushima, T. Fukushima, A. Sakai *et al*: Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies. *Leuk Res Treatment* 2013, 2013:238528.
6. M. A. Den Hoed, E. Lopez-Lopez, M. L. Te Winkel *et al*: Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. *Pharmacogenomics J* 2015, 15(3):248-254.
7. E. Lopez-Lopez, I. Martin-Guerrero, J. Ballesteros *et al*: Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2011, 57(4):612-619.
8. L. R. Treviño, N. Shimasaki, W. Yang *et al*: Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. *J Clin Oncol* 2009, 27(35):5972-5978.
9. J. Li, X. R. Wang, X. W. Zhai *et al*: Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. *International journal of clinical and experimental medicine* 2015, 8(4):6109-6113.
10. E. Lopez-Lopez, J. Ballesteros, M. A. Piñan *et al*: Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. *Pharmacogenet Genomics* 2013, 23(2):53-61.
11. Y. Cheng, M. H. Chen, Q. Zhuang *et al*: Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2021, 68(5):e28858.
12. B. F. Kotnik, J. Jazbec, P. B. Grabar *et al*: Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach. *Radiol Oncol* 2017, 51(4):455-462.
13. Y. Liu, Y. Yin, Q. Sheng *et al*: Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. *PLoS One* 2014, 9(1):e82681.
14. G. Gervasini, S. G. De Murillo, M. Jimenez *et al*: Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia. *Gene* 2017, 628:72-77.
15. M. Yanagimachi, H. Goto, T. Kaneko *et al*: Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. *Int J Hematol* 2013, 98(6):702-707.
16. B. Yazicioglu, Z. Kaya, S. Guntekin Ergun *et al*: Influence of Folate-Related Gene Polymorphisms on High-Dose Methotrexate-Related Toxicity and Prognosis in Turkish Children with Acute Lymphoblastic Leukemia. *Turk J Haematol* 2017, 34(2):143-150.
17. B. Faganel Kotnik, I. Grabnar, P. Bohanec Grabar *et al*: Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. *Eur J Clin Pharmacol* 2011, 67(10):993-1006.
18. M. Kantar, B. Kosova, N. Cetingul *et al*: Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Leuk Lymphoma* 2009, 50(6):912-917.

19. M. A. Esmaili, A. Kazemi, M. Faranoush *et al*: Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. *Iran J Basic Med Sci* 2020, 23(6):800-809.
20. H. Chae, M. Kim, S. H. Choi *et al*: Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia. *J Chemother* 2020, 32(5):251-259.
21. S. Suthandiram, G. G. Gan, S. M. Zain *et al*: Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. *Pharmacogenomics* 2014, 15(11):1479-1494.
22. R. Haase, K. Elsner, N. Merkel *et al*: High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity. *Klin Padiatr* 2012, 224(3):156-159.
23. Y. Shen, Z. Wang, F. Zhou *et al*: The influence of MTHFR genetic polymorphisms on methotrexate therapy in pediatric acute lymphoblastic leukemia. *Open life sciences* 2021, 16(1):1203-1212.
24. F. T. Zahra, N. A. Nahid, M. R. Islam *et al*: Pharmacogenetic Variants in MTHFR Gene are Significant Predictors of Methotrexate Toxicities in Bangladeshi Patients With Acute Lymphoblastic Leukemia. *Clin Lymphoma Myeloma Leuk* 2020, 20(2):e58-e65.
25. A. M. Yousef, R. Farhad, D. Alshamaseen *et al*: Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia. *Cancer Chemother Pharmacol* 2019, 83(4):755-762.
26. A. Ongaro, M. De Mattei, M. G. Della Porta *et al*: Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. *Haematologica* 2009, 94(10):1391-1398.
27. D. S. Eissa, T. M. Ahmed: C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia. *Blood Coagul Fibrinolysis* 2013, 24(2):181-188.
28. P. Chiusolo, S. Giammarco, S. Bellesi *et al*: The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. *Cancer Chemother Pharmacol* 2012, 69(3):691-696.
29. J. Han, L. Liu, L. Meng *et al*: Effect of Polymorphisms of ABCB1 and MTHFR on Methotrexate-Related Toxicities in Adults With Hematological Malignancies. *Frontiers in oncology* 2021, 11:759805.
30. N. Erculj, B. F. Kotnik, M. Debeljak *et al*: Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. *Leuk Lymphoma* 2012, 53(6):1096-1104.
31. S. G. Liu, Z. G. Li, L. Cui *et al*: Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. *Leuk Lymphoma* 2011, 52(6):1030-1040.
32. R. Ramalingam, H. Kaur, J. X. Scott *et al*: Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients. *Cancer Chemother Pharmacol* 2022, 89(3):393-400.
33. N. Kotur, J. Lazic, B. Ristivojevic *et al*: Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment. *Genes (Basel)* 2020, 11(4).
34. R. Frikha, M. B. Jemaa, F. Frikha *et al*: Involvement of C677T MTHFR variant but not A1298C in methotrexate-induced toxicity in acute lymphoblastic leukemia. *J Oncol Pharm Pract* 2020:1078155220951898.
35. L. B. Mahmoud, M. Mdhaffar, R. Frikha *et al*: Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic

leukemia. *Adv Clin Exp Med* 2018, 27(8):1061-1068.

36. N. M. El-Khodary, S. M. El-Haggar, M. A. Eid *et al*: Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. *Med Oncol* 2012, 29(3):2053-2062.
37. A. Ramirez-Pacheco, S. Moreno-Guerrero, I. Alamillo *et al*: Mexican Childhood Acute Lymphoblastic Leukemia: A Pilot Study of the MDR1 and MTHFR Gene Polymorphisms and Their Associations with Clinical Outcomes. *Genet Test Mol Biomarkers* 2016, 20(10):597-602.
38. A. Giletti, M. Vital, M. Lorenzo *et al*: Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases. *Eur J Pharm Sci* 2017, 109:480-485.
39. I. Costea, A. Moghrabi, C. Laverdiere *et al*: Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. *Haematologica* 2006, 91(8):1113-1116.
40. G. J. Ruiz-Arguelles, L. N. Coconi-Linares, J. Garces-Eisele *et al*: Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. *Hematology* 2007, 12(5):387-391.